Muhammad Mir, MD
Pulmonary Disease · Fort Smith, ARNPI 1538460951
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,761 of the $4,015 with a category attached, or 68.8%. 24 manufacturers reported payments, led by Olympus Corporation Of The Americas at 31.3% of the total. Reporting peaked in 2023 at $1,586 and has fallen 70.4% since, to $469 in 2025. That places this record below the midpoint for pulmonary disease clinicians in AR, where the typical reported total is $3,332.
Across 178 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$1K
- GSK$576
- AstraZeneca$392
- Boehringer Ingelheim$371
- Regeneron Healthcare Solutions, Inc.$303
- Actelion Pharmaceuticals US, Inc.$249
- plus $870 from 18 others
What the payments were for
- Travel & lodging$1,18429%
- Food & beverage$2,76169%
- Education$702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 12 | $1,256 |
| GSK | 49 | $576 |
| AstraZeneca | 24 | $392 |
| Boehringer Ingelheim | 26 | $371 |
| Regeneron Healthcare Solutions, Inc. | 11 | $303 |
| Actelion Pharmaceuticals US, Inc. | 11 | $249 |
| Sanofi | 8 | $158 |
| Baxter Healthcare | 8 | $133 |
| Amgen | 6 | $105 |
| United Therapeutics Corporation | 4 | $82 |
| Itamar Medical Inc | 1 | $59 |
| Inspire Medical Systems, Inc. | 2 | $58 |
| Genentech USA, Inc. | 3 | $52 |
| Electromed, Inc. | 2 | $32 |
| Mylan Specialty L.p. | 2 | $26 |
| Verona Pharma, Inc. | 1 | $24 |
| Insmed, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Inogen, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SINGLE USE SUCTION VALVE (Sterile)$975
- Olympus$397
- ViziShot 2 FLEX$139
- DUPIXENT$116
How this compares
$4,015 in reported general payments places this provider in the 50th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 594 | $486,317 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $48,503 |
| Spiriva RespimatTiotropium Bromide | 33 | $24,548 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $19,274 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $18,218 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,026 |
| EliquisApixaban | 15 | $8,122 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $7,112 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $5,892 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $5,309 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 136 | $4,261 |
| Azelastine Hcl | 64 | $2,204 |
| Azithromycin | 44 | $1,920 |
| Montelukast Sodium | 258 | $1,887 |
| Ventolin HfaAlbuterol Sulfate | 23 | $1,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $576 | $526,674662 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $392 | $67,777123 claims |
| Boehringer IngelheimSpiriva Respimat | $371 | $24,54833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Fort Smith
- Arturo MeadeFort Smith$67K
- Daphne MacbruceFort Smith$10K
- Adebayo FasanyaFort Smith$8K
- Sarikun TjandraFort Smith$3K
- Francisco TamayoFort Smith$3K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.